Stoke Therapeutics (STOK) FCF Margin (2022 - 2026)

Stoke Therapeutics' FCF Margin history runs 5 years deep, the most recent figure standing at 978.25% for Q1 2026.

• In Q1 2026, FCF Margin fell 106137.0% year-over-year to 978.25%; the TTM figure through Mar 2026 stood at 460.79% (down 49710.0% YoY), while the FY2025 annual figure was 24.35%, up 26250.0% from the prior year.
• FCF Margin for Q1 2026 stood at 978.25%, up from 2213.41% in the prior quarter.
• The five-year high for FCF Margin was 1055.0% in Q1 2022, with the low at 2213.41% in Q4 2025.
• The 5-year median for FCF Margin is 533.4% (2023), against an average of 509.38%.
• Peak annual rise in FCF Margin reached 66595 bps in 2025, while the deepest fall reached 211000 bps in 2025.
• Stoke Therapeutics' FCF Margin stood at 675.89% in 2022, then retreated by 10 bps to 745.11% in 2023, then jumped by 86 bps to 103.41% in 2024, then sank by 2040 bps to 2213.41% in 2025, then jumped by 56 bps to 978.25% in 2026.
• Business Quant data shows STOK's FCF Margin at 978.25% in Q1 2026, 2213.41% in Q4 2025, and 286.0% in Q3 2025.